First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence.

Journal Information

Full Title: Public Health

Abbreviation: Public Health

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Public Health

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"in fully vaccinated adults (please see the supplementary data 1 ) we documented that participants with a longer interval from the last vaccine shot and illness onset (6 or more months) had a slight but significantly reduced risk for developing severe illness (vs <6 months: rr = 1 002 95% ci 1 001-1 003).; however we consider that most of these infections correspond to the variant of interest given (1) the documented peak in the incidence of covid-19 in mexico during the study period (please see the supplementary data 2 ) and (2) in the united states and also during the end of 2021 of start of 2022 the omicron variant was identified in nearly 99% of genomic sequences."

Code Sharing
Evidence found in paper:

"Competing interests None declared."

Evidence found in paper:

"Funding None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025